207 related articles for article (PubMed ID: 16359319)
21. Cryptococcus neoformans survive and replicate in human microglia.
Lee SC; Kress Y; Zhao ML; Dickson DW; Casadevall A
Lab Invest; 1995 Dec; 73(6):871-9. PubMed ID: 8558850
[TBL] [Abstract][Full Text] [Related]
22. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.
Nimrichter L; Frases S; Cinelli LP; Viana NB; Nakouzi A; Travassos LR; Casadevall A; Rodrigues ML
Eukaryot Cell; 2007 Aug; 6(8):1400-10. PubMed ID: 17573547
[TBL] [Abstract][Full Text] [Related]
23. Cryptococcus neoformans capsule biosynthesis and regulation.
Janbon G
FEMS Yeast Res; 2004 Sep; 4(8):765-71. PubMed ID: 15450183
[TBL] [Abstract][Full Text] [Related]
24. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
25. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.
Pericolini E; Cenci E; Monari C; De Jesus M; Bistoni F; Casadevall A; Vecchiarelli A
Cell Microbiol; 2006 Feb; 8(2):267-75. PubMed ID: 16441437
[TBL] [Abstract][Full Text] [Related]
26. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages.
Chrisman CJ; Albuquerque P; Guimaraes AJ; Nieves E; Casadevall A
PLoS Pathog; 2011 May; 7(5):e1002047. PubMed ID: 21637814
[TBL] [Abstract][Full Text] [Related]
27. Effect of hypertonic solutes upon the polysaccharide capsule in Cryptococcus neoformans.
Jacobson ES; Tingler MJ; Quynn PL
Mycoses; 1989 Jan; 32(1):14-23. PubMed ID: 2664504
[TBL] [Abstract][Full Text] [Related]
28. Drastic reduction in the virulence of Streptococcus pneumoniae expressing type 2 capsular polysaccharide but lacking choline residues in the cell wall.
Kharat AS; Tomasz A
Mol Microbiol; 2006 Apr; 60(1):93-107. PubMed ID: 16556223
[TBL] [Abstract][Full Text] [Related]
29. Cryptococcus neoformans inhibits nitric oxide synthesis caused by CpG-oligodeoxynucleotide-stimulated macrophages in a fashion independent of capsular polysaccharides.
Xiao G; Miyazato A; Inden K; Nakamura K; Shiratori K; Nakagawa K; Miyazawa T; Suzuki K; Kaku M; Kawakami K
Microbiol Immunol; 2008 Mar; 52(3):171-9. PubMed ID: 18402599
[TBL] [Abstract][Full Text] [Related]
30. Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan.
Rodrigues ML; Alvarez M; Fonseca FL; Casadevall A
Eukaryot Cell; 2008 Apr; 7(4):602-9. PubMed ID: 18039942
[TBL] [Abstract][Full Text] [Related]
31. A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule.
Park YD; Shin S; Panepinto J; Ramos J; Qiu J; Frases S; Albuquerque P; Cordero RJ; Zhang N; Himmelreich U; Beenhouwer D; Bennett JE; Casadevall A; Williamson PR
PLoS Pathog; 2014 May; 10(5):e1004037. PubMed ID: 24789368
[TBL] [Abstract][Full Text] [Related]
32. The Capsule of Cryptococcus neoformans Modulates Phagosomal pH through Its Acid-Base Properties.
De Leon-Rodriguez CM; Fu MS; Çorbali MO; Cordero RJB; Casadevall A
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355667
[TBL] [Abstract][Full Text] [Related]
33. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival.
Zaragoza O; Chrisman CJ; Castelli MV; Frases S; Cuenca-Estrella M; Rodríguez-Tudela JL; Casadevall A
Cell Microbiol; 2008 Oct; 10(10):2043-57. PubMed ID: 18554313
[TBL] [Abstract][Full Text] [Related]
34. Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection.
García-Rodas R; Casadevall A; Rodríguez-Tudela JL; Cuenca-Estrella M; Zaragoza O
PLoS One; 2011; 6(9):e24485. PubMed ID: 21915338
[TBL] [Abstract][Full Text] [Related]
35. Strains of Cryptococcus neoformans with defined capsular phenotypes.
Jacobson ES; Tingler MJ
J Med Vet Mycol; 1994; 32(5):401-4. PubMed ID: 7844706
[TBL] [Abstract][Full Text] [Related]
36. Influence of indinavir on virulence and growth of Cryptococcus neoformans.
Monari C; Pericolini E; Bistoni G; Cenci E; Bistoni F; Vecchiarelli A
J Infect Dis; 2005 Jan; 191(2):307-11. PubMed ID: 15609242
[TBL] [Abstract][Full Text] [Related]
37. Budding of melanized Cryptococcus neoformans in the presence or absence of L-dopa.
Nosanchuk JD; Casadevall A
Microbiology (Reading); 2003 Jul; 149(Pt 7):1945-1951. PubMed ID: 12855745
[TBL] [Abstract][Full Text] [Related]
38. The isolation and characterization of virulence factors of Cryptococcus spp. from saprophytic sources in the city of Ribeirão Preto, São Paulo, Brazil.
Pedroso RS; Ferreira JC; Candido RC
Microbiol Res; 2009; 164(2):221-7. PubMed ID: 17428645
[TBL] [Abstract][Full Text] [Related]
39. Temporal behavior of capsule enlargement by Cryptococcus neoformans.
Cordero RJ; Bergman A; Casadevall A
Eukaryot Cell; 2013 Oct; 12(10):1383-8. PubMed ID: 23954840
[TBL] [Abstract][Full Text] [Related]
40. Glucuronoxylomannan exhibits potent immunosuppressive properties.
Monari C; Bistoni F; Vecchiarelli A
FEMS Yeast Res; 2006 Jun; 6(4):537-42. PubMed ID: 16696649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
